Helena Rodbard
Endocrinology, Diabetes & Metabolism · Rockville, MDNPI 1346260841
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Lilly USA, LLC at 37.0% of the total. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 458 payments — averaging $1022.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$173K
- Sanofi-aventis U.S. LLC$68K
- Merck$45K
- Novo Nordisk$41K
- Boehringer Ingelheim$40K
- Pacira Pharmaceuticals Incorporated$34K
- plus $67K from 17 others
Across 969 payments — averaging $2108.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.6M
- Novo Nordisk AS$359K
- Sanofi US Services Inc.$108K
- Sanofi-aventis U.S. LLC$11K
- Bayer$6K
- Eli Lilly Export S.A. Puerto Rico Branch$5K
- plus $1K from 1 others
What the payments were for
- Consulting fees$136,89029%
- Speaking & faculty fees$256,43855%
- Travel & lodging$63,89314%
- Food & beverage$11,0662%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 176 | $173,253 |
| Sanofi-aventis U.S. LLC | 51 | $67,930 |
| Merck | 42 | $45,314 |
| Novo Nordisk | 33 | $41,300 |
| Boehringer Ingelheim | 50 | $39,912 |
| Pacira Pharmaceuticals Incorporated | 19 | $34,078 |
| Bayer | 10 | $18,380 |
| Eli Lilly | 31 | $13,816 |
| Ionis Pharmaceuticals, Inc. | 12 | $11,750 |
| Vivus LLC | 5 | $6,960 |
| Johnson & Johnson | 7 | $5,775 |
| Lexicon Pharmaceuticals, Inc. | 4 | $3,649 |
| Dexcom, Inc. | 3 | $2,295 |
| Regeneron | 1 | $1,825 |
| Zealand Pharma US, Inc. | 1 | $950 |
| Mannkind Corporation | 3 | $295 |
| Medtronic(2 entities) | 3 | $252 |
| Tandem Diabetes Care, Inc. | 2 | $235 |
| Ascensia Diabetes Care US Inc. | 1 | $80 |
| Antares Pharma, Inc. | 1 | $80 |
| Corcept Therapeutics | 1 | $75 |
| Madrigal Pharmaceuticals | 1 | $54 |
| Intuity Medical Inc | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$468,296 in reported general payments places this provider in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 44 | $76,660 |
| JardianceEmpagliflozin | 32 | $50,125 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $15,039 |
| SynthroidLevothyroxine Sodium | 119 | $12,867 |
| Atorvastatin Calcium | 42 | $541 |
| Metformin Hcl | 30 | $438 |
| Metformin Hcl ErMetformin Hcl | 16 | $352 |
| UnithroidLevothyroxine Sodium | 13 | $277 |
| Alendronate Sodium | 22 | $206 |
| Levothyroxine Sodium | 25 | $197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $173,253 | $76,66044 claims |
| Boehringer IngelheimJardiance | $39,912 | $50,12532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Rockville
- David BrownRockville$497K
- Gerti TashkoRockville$106K
- Jie HeRockville$26K
- Monika MannanRockville$8K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- Philip LevinBaltimore$489K
- Roy PhillipsBel Air$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.